News & Updates

A technology-enabled virtual ward may be a feasible alternative to hospitalization for high-risk COVID-19 patients such as the elderly and the immunocompromised, a retrospective cohort study from Singapore suggests.

In the treatment of patients with mild-to-moderate COVID-19, adding fluvoxamine to favipiravir does not appear to prevent disease progression or improve certain outcomes, according to the results of an open-label study.

More evidence suggests that people exposed to more air pollution during the pandemic are at greater risk for COVID-19 infection, hospitalization, and death, but the exact mechanism behind the link is unknown.

In the PRO analyses of the phase III CodeBreak 200 trial, the first-in-class KRAS^G12C inhibitor sotorasib improved quality of life (QoL) of patients with pretreated KRAS^G12C-mutated advanced non-small-cell lung cancer (NSCLC) compared with docetaxel.